Capella BioScience Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $9.8M
Latest Deal Amount
  • Investors
  • 6

Capella BioScience General Information

Description

Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mAbs therapeutics. The company's medicines leverage novel technologies to develop therapeutics, enabling researchers to research on the latest medical technology based drugs for oncology and autoimmune disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 158-160 North Gower Street
  • London NW1 2ND
  • England, United Kingdom

Capella BioScience Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Capella BioScience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 24-Sep-2020 $9.8M 000.00 0000 Completed Generating Revenue
3. Early Stage VC 16-Aug-2019 00.00 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series A) 03-Apr-2016 $15.7M $18.1M Completed Generating Revenue
1. Seed Round 22-Dec-2014 $2.35M $2.35M Completed Generating Revenue
To view Capella BioScience’s complete valuation and funding history, request access »

Capella BioScience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B Shares 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
Preference 0,000,000 00.000000 00.00 00.00 00 00.00 00.000
A Shares 2,171,715 $0.001306 $2.59 $2.59 1x $2.59 1.73%
Seed 1,500,000 $0.001306 $1.31 $1.31 1x $1.31 17.12%
To view Capella BioScience’s complete cap table history, request access »

Capella BioScience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of monoclonal antibody medicines (mAbs) intended to discover, develop, and commercialize medicines based on mA
Drug Discovery
London, United Kingdom
000.00
000 0000-00-00
0000000000 0 000.00

00000000

dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliq
0000000000000
Heidelberg, Germany
00 As of 0000
000.00
0000000000 000.00

000 0000

aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cill
0000000000000
Nantes, France
00 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Capella BioScience Competitors (6)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apogenix Venture Capital-Backed Heidelberg, Germany 00 000.00 0000000000 000.00
000 00000000000000 Corporation Nantes, France 00 000.00 000000000 000.00
0000000 Corporation Princeton, NJ 00 00000 000000000 00000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000&0
0000000 0000000000 Formerly VC-backed Heidelberg, Germany 000 00000 00000000000 00000
To view Capella BioScience’s complete competitors history, request access »

Capella BioScience Executive Team (4)

Name Title Board Seat Contact Info
Steve Holmes Ph.D Founder, Board Member & Chief Operating Officer
Rajesh Parekh Ph.D Clinical and Scientific Advisor
Donald Drakeman Ph.D Clinical and Scientific Advisor
Kevin Johnson Ph.D Clinical and Scientific Advisor
To view Capella BioScience’s complete executive team members history, request access »

Capella BioScience Board Members (2)

Name Representing Role Since
Steve Holmes Ph.D Capella BioScience Founder, Board Member & Chief Operating Officer 000 0000
William Harrington MD Osage Venture Partners Board Observer 000 0000
To view Capella BioScience’s complete board members history, request access »

Capella BioScience Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Medicxi Venture Capital Minority 000 0000 000000 0
Osage University Partners Venture Capital Minority 000 0000 000000 0
Advent Life Sciences Venture Capital Minority 000 0000 000000 0
Data Collective Venture Capital Minority 000 0000 000000 0
Farzad Nazem Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »